17 results about "Macrophage migration inhibitory factor" patented technology

Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

The present disclosure provides methods for preventing, treating, or delaying progression of neuroinflammatory CNS conditions, e.g., Alzheimer's disease, by administration of an agent that inhibits macrophage migration inhibitory factor (MIF)-CD74 signaling. In some embodiments the agent to be administered is a MIF-binding protein such as a MIF antibody. In other embodiments disclosed herein the agent is a targeting polynucleotide against MIF or CD74.

The present application provides a compound of Formula (I): [Formula I] or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, W, L, R8, and R9 are as described herein. Pharmaceutical compositions including these compounds and methods of using these compounds for treating parasitic infections (e.g., malaria), cancer, cardiovascular diseases, neurological diseases, inflammatory diseases, neuropathic pain, and other conditions are also disclosed herein.

Compositions, systems, and advanced methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition that inhibits at least one of immunomodulatory cytokine such as (but not limited to) macrophage migration inhibitory factor (MIF), MHC class I chain-related polypeptide A (MICA), and / or MHC class I chain-related polypeptide B (MICB).

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and / or conditions with the compounds or the composition. The disease states and / or conditions are mediated through MIF / IgG or where MIF / IgG is a contributing factor to the development and perpetuation of diseases and / or conditions, such as autoimmune diseases and cancer, among others.

Provided herein are novel compounds as inhibitors of macrophage migration inhibitory factor (MIF) pharmaceutical compositions comprising the compounds provided herein: as well as uses and methods for treating a disease mediated by MIF by administering the compounds provided herein. In particular, the compounds of the invention may be used as MIF inhibitors.

The invention provides a biomarker for diagnosing post-traumatic stress disorder and application of the biomarker, and belongs to the technical field of artificial intelligence medical treatment. The biomarker comprises at least one of matrix metallopeptidase 14, alpha1-antitrypsin, a macrophage migration inhibition factor, a tryptophan-tRNA ligase and a cell growth factor activator. The marker has high sensitivity and specificity in diagnosis of the post-traumatic stress disorder, can effectively diagnose the post-traumatic stress disorder in an early stage, provides a treatment target for subsequent treatment of the post-traumatic stress disorder, and has good clinical use and popularization and application values.

This invention provides a biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions, its preparation method, and its application. The biomimetic nanoparticle composite PRP hydrogel is formed by cross-linking a hydrogel matrix and composite nanoparticles dispersed therein. The core of the composite nanoparticles is albumin nanoparticles loaded with macrophage migration inhibitory factor inhibitors, and the outer shell of the composite nanoparticles is a fibroblast membrane. The preparation method includes the following steps: preparing a composite nanoparticle dispersion; mixing sodium alginate with the composite nanoparticle dispersion to prepare a sodium alginate solution; adding platelet-rich plasma and mixing evenly; adding calcium carbonate and an acidity regulator; stirring evenly and allowing to stand to form a gel, thus obtaining the biomimetic nanoparticle composite PRP hydrogel with anti-fibrotic and anti-inflammatory functions.

A method for reducing macrophage migration inhibitory factor (MIF or MMIF) cytokine or its biological activity, including the step of administering an isothiocyanate functional surfactant to a patient having a disease or condition wherein MIF cytokine or its biological activity is implicated in the disease or condition. In one embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure:

The present disclosure relates to methods and kits for diagnosing pancreatic cancer and monitoring disease load in patients diagnosed with pancreatic cancer, the method comprises the quantitative determination of the concentration of extracellular vesicles in a sample of a bodily fluid of a patient that are positive against one, two or three markers selected from the group consisting of thrombin-sensitive protein-2 (THBS2), placental alkaline phosphatase-like protein 2 (ALPPL2) and macrophage migration inhibition factor (MIF).

Provided herein are novel compounds as inhibitors of macrophage migration inhibitory factor (MIF), pharmaceutical compositions comprising the compounds provided herein, and uses and methods for treating diseases mediated by MIF by administering the compounds provided herein. In particular, the compounds of the present invention can be used as MIF inhibitors.

The present invention provides a compound of formula I that can be used as an inhibitor of macrophage migration inhibitory factor (MIF); a method for preparing the compound of the present invention; a pharmaceutical composition comprising the compound of the present invention; and the use and method of treating MIF-mediated diseases by administering the compound of the present invention.

Provided herein are methods of reducing immune checkpoint therapy resistance, increasing immune checkpoint therapy sensitivity and / or increasing anti-tumor activity in subjects with cancer, methods of treating non-small cell lung cancer (NSCLC), and methods of identifying a subject as a responder to a macrophage migration inhibitory factor (MIF) targeting agent therapy. The methods include identifying alteration in the KEAP1 / NRF2 pathway and administering MIF targeting agent therapy. Illustrative immune checkpoint therapies include PD-1 inhibitors and / or PD-L1 inhibitors.

The present invention relates to a fusion polypeptide derived from Toxoplasma gondii. The fusion polypeptide can be used as a pharmaceutical composition for treating tuberculosis. In particular, the fusion polypeptide according to the present invention acts specifically on the lungs infected with Mycobacterium tuberculosis and has therapeutic efficacy even against tuberculosis having resistance to isoniazid (INH), pyrazinamide (PZA), rifampin (RFP), and / or streptomycin (SM).

The disclosure concerns methods and kits of diagnosis of pancreatic cancer and monitoring disease burden in patients diagnosed with pancreatic cancer, the method comprising quantitative determination of the concentration of extracellular vesicles that are positive for one, two or three markers selected from thrombospondin-2 (THBS2), alkaline phosphatase placental-like 2 (ALPPL2), and macrophage migration inhibitory factor (MIF) in the patients' fluid samples.